Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is a phase 1/2, interventional study registered as NCT02830724 by National Cancer Institute (NCI), with a registry enrolment figure of 124 participants, started 2017-04-06 and due to reach its primary completion in 2029-01-01. Interventions recorded: Cyclophosphamide; Fludarabine; Aldesleukin; Anti-hCD70 CAR transduced PBL. Conditions listed: Pancreatic Cancer; Renal Cell Cancer; Breast Cancer; Melanoma; Ovarian Cancer. Primary outcome: Frequency and severity of treatment-related adverse events; Response rate. Sites: United States. No results are recorded here; the registry entry is the source.